8-K current report · filed Nov 12, 2026

Kodiak Sciences Inc. (KOD) 8-K Current Report: November 12, 2026

Item 2.02Item EX-99.1KOD overview

Short answer

Kodiak Sciences Inc. (KOD) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Q3 2026 financial results for quarter ended September 30, 2026.

Kodiak Sciences Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers Q3 2026 financial results for quarter ended September 30, 2026
  • Business highlights accompany the quarterly results
  • Exhibit 99.1 contains the detailed financial results and operating updates

Item EX-99.1 · Exhibit EX-99.1

  • Zenkuda met DAYBREAK’s primary endpoint with p-value 0.0007, 54% of patients achieving 6-month dosing, supporting planned multi-indication BLA submission in Q4 2026
  • Tabirafusp-ted met vision and anatomical endpoints with p-values 0.0036 and <0.0001, while Phase 3 ALTO enrollment advances in diabetic macular edema
  • KSI-101 PEAK first 300-patient cohort completed, with pivotal topline data expected December 2026 and potential BLA filing targeted for Q2 2027
  • Cash $88.7M at September 30, 2026, supplemented by $69M net ATM proceeds after quarter-end, extending operations into 2027
  • Q3 net loss $66.2M, or $1.05 per share, with R&D expense rising to $58.3M as late-stage trial and manufacturing activity accelerates

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Kodiak Sciences Inc. 8-K filings

Get the next KOD 8-K as it lands

Follow KOD for push alerts, or ask the research agent what this filing means.